Screener
Ligand Pharmaceuticals LGND Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Trade name | 2,642 | 2,642 |
| Less: accumulated amortization | (2,043) | (1,976) |
| Customer relationships | 29,600 | 29,600 |
| Less: accumulated amortization | (22,889) | (22,144) |
| Contractual relationships | 360,000 | 360,000 |
| Less: accumulated amortization | (165,922) | (151,494) |
| Total definite lived intangible assets | 209,244 | 225,438 |
| Total goodwill and other identifiable intangible assets, net | $310,785 | $326,979 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's intangibles (net)?
- Ligand Pharmaceuticals (LGND) reported intangibles (net) of $209.24M in Q2 2026.
- How has Ligand Pharmaceuticals's intangibles (net) changed year-over-year?
- Ligand Pharmaceuticals's intangibles (net) decreased by 16.3% year-over-year, from $250.13M to $209.24M.
- What is the long-term trend for Ligand Pharmaceuticals's intangibles (net)?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's intangibles (net) has grown at a -17.7% compound annual growth rate (CAGR), from $595.33M to $225.44M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about Ligand Pharmaceuticals's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude